CareLit Fachartikel
Treatment of high-risk MDS patients: State of the art
M Lübbert · TumorDiagnostik & Therapie · 2014 · Heft 10
Dokument
932686
CareLit-ID
Jahr
2014
Publikation
PDF
nein
Metadaten
DOI
ja
zitierfähig
Bibliografische Angaben
Zusammenfassung
The treatment options for high-risk MDS patients, whether non-curative (due to age, comorbidities, reduced performance status etc.) or curative (because of a viable option of allogeneic stem cell transplantation) have clearly grown recently. 5-azacytidine (Vidaza, 5-aza) was FDA- and EMA-approved for the treatment of MDS (EMA: IPSS higher-risk) and patients with 20–30% blasts (formerly categorized as MDS RAEB-t, AML according to WHO). Efficacy of this treatment in MDS was confirmed in several “real-world” retrospective analyses and named-patient programs; not surprisingly the outcome described in such post-appro…
Schlagworte
Decitabine
Attention
Blood
Lead
Transplantation
TumorDiagnostik & Therapie
